• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    bioAffinity Technologies, Inc. - Common Stock (NQ: BIAF )

    1.380 +0.010 (+0.73%)
    Streaming Delayed Price Updated: 2:08 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 9,651
    Open 1.370
    Bid (Size) 1.380 (1)
    Ask (Size) 1.390 (27)
    Prev. Close 1.370
    Today's Range 1.360 - 1.390
    52wk Range 1.250 - 3.620
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
    From bioAffinity Technologies, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -18.34%
    -18.34%
    1 Month
    -24.18%
    -24.18%
    3 Month
    -16.36%
    -16.36%
    6 Month
    -29.95%
    -29.95%
    1 Year
    +0.73%
    +0.73%

    More News

    Read More
    bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
    From bioAffinity Technologies, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
    From bioAffinity Technologies, Inc.
    Via Business Wire
    Are Pharma Stocks Harmful To Your Financial Health ?
    Via Talk Markets
    bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
    From bioAffinity Technologies, Inc.
    Via Business Wire
    BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q2 2024
    Via InvestorPlace
    bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
    From bioAffinity Technologies, Inc.
    Via Business Wire
    Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
    From bioAffinity Technologies, Inc.
    Via Business Wire
    Crude Oil Falls Sharply; Exxon Mobil Earnings Top Views
    Via Benzinga
    Exposures Fossil Fuels
    Nasdaq Tumbles 3%; US Economy Adds 114,000 Jobs In July
    Via Benzinga
    Topics Economy
    Exposures Economy
    Dow Dips Over 400 Points; Apple Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
    From bioAffinity Technologies, Inc.
    Via Business Wire
    BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
    From bioAffinity Technologies, Inc.
    Via Business Wire
    BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q1 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.